The ASM will serve as the launch pad for AMBS in t
Post# of 30028
Posted On: 10/12/2014 5:22:54 PM
The ASM will serve as the launch pad for AMBS in the coming quarters. Clearly, AMBS has the solid support of shareholders in advancing their business model into 2015 and beyond. Dr. Rubinfeld summed it up well by simply stating, "we're there!", meaning that AMBS is at a pivot point where revenue realization will enable AMBS to advance business plans forward into 2015:
1)Lympro commercialization; first RUO then CLIA and FDA approval; sales to begin this quarter.
2) Eltoprazine phase 2b launch in preparation for PD levodopa with an excellent safety profile already established
3) MANF IND's; specifically RP, then Retinal Vein Occlusion and Glaucoma; Wolfram's disease. ANY one of these could ignite the enthusiasm of investors.
4) Up listing to a national exchange....following milestone achievements, and as Mkt conditions allow.
Just the tip of the iceberg with what is actively underway. The 8k does nothing but help us all to understand more clearly the catalysts that are going to drive the pps north in the coming weeks. Granted, Gerald has made some blunders, but then what CEO hasn't?
I can still remember a discussion re. AMBS future back about two years ago when someone mentioned the interest in AMBS pipeline way back then by some BP players, and the hopes of some that they would fail, and that assets could be picked up on the cheap. Those days are over. Our present pps is grossly undervalued. We may presently have some very big players making sure it stays there for many reasons. With everything that AMBS has going right now, one major announcement could break our trajectory north in a hurry! Like Dr. Rubinfeld said, "We're there!" Exciting days and weeks ahead for AMBS!!
1)Lympro commercialization; first RUO then CLIA and FDA approval; sales to begin this quarter.
2) Eltoprazine phase 2b launch in preparation for PD levodopa with an excellent safety profile already established
3) MANF IND's; specifically RP, then Retinal Vein Occlusion and Glaucoma; Wolfram's disease. ANY one of these could ignite the enthusiasm of investors.
4) Up listing to a national exchange....following milestone achievements, and as Mkt conditions allow.
Just the tip of the iceberg with what is actively underway. The 8k does nothing but help us all to understand more clearly the catalysts that are going to drive the pps north in the coming weeks. Granted, Gerald has made some blunders, but then what CEO hasn't?
I can still remember a discussion re. AMBS future back about two years ago when someone mentioned the interest in AMBS pipeline way back then by some BP players, and the hopes of some that they would fail, and that assets could be picked up on the cheap. Those days are over. Our present pps is grossly undervalued. We may presently have some very big players making sure it stays there for many reasons. With everything that AMBS has going right now, one major announcement could break our trajectory north in a hurry! Like Dr. Rubinfeld said, "We're there!" Exciting days and weeks ahead for AMBS!!
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼